Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 207206, held by Visum Pharma. Metoprolol Succinate.
As of Nov 21, 2026, ANDA 207206 (Metoprolol Succinate), held by Visum Pharma, was first approved by FDA on Dec 19, 2018, with 2 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets, metoprolol succinate, beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 19, 2018 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Rx |
| Nov 4, 2024 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Nov 4, 2024 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Dec 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters